Duo Oncology

About

Duo Oncology, founded by oncologists, is developing tumor-penetrating nanomedicines to upgraded the foundations of cancer medicine. Duo’s patented platform prodrug chemistry releases creates nanomedicines that penetrate established tumors to reduce toxicity and improve patient outcomes.

Product

Value proposition

Developing tumor-activated prodrug combinations to replace toxic multi-agent chemotherapy with single medicines that concentrate activity in tumors while limiting healthy-tissue exposure.

Regulatory

Clinical-stage; adaptive Phase 1b/2 trial ongoing

Founders

• Sam Rothstein — CEO and Cofounder
• Song Li — Cofounder and Lead Inventor

Categories

Products

Key features

Technologies

Target conditions

Care settings

Certifications

Partnerships

Traction metrics

Investors

News

• Fighting Cancer: Pitt Startup Duo Oncology Prepares for Nanomedicine Clinical Trials · 2025-04-08T12:42:32.000Z
• Duo Oncology | MTEC · 2026-05-13T00:00:00.000Z
• "The New Chemotherapy": Duo Oncology Introduces First Innovative Cancer-Fighting Nanomedicine in Over a Decade · 2024-10-15T07:34:12.000Z
• Duo Oncology raises $400,000 Seed round (June 2025) · 2025-06-10T17:40:36.000Z
• Lead Product DUO-207 Completes Clean GLP Toxicology Studies. — Duo Oncology · 2025-08-14T18:15:00.000Z
• Duo Oncology Secures U.S. Composition of Matter Patent for Platform Chemistry and Lead Product. — Duo Oncology · 2025-02-13T20:30:00.000Z

Browse related software

• Clinic software in PA
• Clinic software in Pittsburgh
• BioTech software
• Oncology software
• Drug development software
• All clinic software companies A–Z

More links